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Abstract
Background: The cblC defect is a rare inborn error of intracellular cobalamin metabolism. Biochemical hallmarks
are elevated homocysteine and low methionine in plasma accompanied by methylmalonic aciduria. Due to the
heterogeneous clinical picture, patients with the late-onset form of the disease (onset >12 months) come to the
attention of diverse medical specialists, e.g. paediatricians, neurologists, nephrologists, psychiatrists or haematologists.
The report reviews the published clinical data and adds three new cases to raise awareness for this severe but often
treatable disease.
Methods: The Pubmed and the Cochrane databases were searched for clinical reports on cblC patients and three
unreported cases are presented to illustrate the clinical spectrum.
Results: Reports on 58 cases (30 females, 22 males, 6 = no information) and the three new cases underlined the clinical
heterogeneity of the disease. Time between first symptoms and diagnosis ranged from three months to more than
20 years. Haemolytic uraemic syndrome and pulmonary hypertension were main presenting symptoms in preschool
children. In older children/adolescents, psychiatric symptoms, cognitive impairment, ataxia and myelopathy were
frequently observed while thromboembolic events and glomerulopathies were almost exclusively seen in adults. Brain
atrophy, white matter lesions and myelopathy were frequently encountered. The majority of patients showed marked
biochemical and clinical response to treatment with parenteral hydroxocobalamin combined with oral betaine, folate,
carnitine and rarely methionine. The course was less favourable in late treated or untreated patients.
Conclusions: The late-onset cblC defect is a rare disease and unfortunately, diagnosis is often delayed. Raising
awareness for this disorder can significantly improve patients’ outcome and perspective by timely initiation of targeted
treatment. Newborn screening (NBS) for the cblC defect might be of benefit especially for late-onset patients since
treatment seems efficient when initiated before irreversible organ damage. In general, inborn errors of metabolisms
should be considered in unexplained medical cases at any age, especially in patients with multisystemic disease. More
specifically, total homocysteine in plasma and methylmalonic acid in urine/plasma should be measured in unexplained
neurologic, psychiatric, renal, haematologic and thromboembolic disease.
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Background
The cblC defect (ORPHA 79282; MIM 277400) is an
inborn error of intracellular cobalamin (cbl) metabolism
caused by mutations in the MMACHC gene, which is
located on chromosome 1p34.1 [1]. Due to the defective
MMACHC gene product, methylcobalamin and adeno-
sylcobalamin cannot be synthesized. Since methylcobala-
min is the essential cofactor for the enzyme methionine
synthase, the defect causes an impairment of the remethy-
lation of homocysteine (Hcy) to methionine (Met). Ade-
nosylcobalamin is cofactor for the mitochondrial enzyme
methylmalonyl-CoA mutase, a critical enzyme in the deg-
radation of methylmalonic acid (MMA) [2]. Biochemical
markers for the disease are elevated total Hcy (tHcy) in
plasma and MMA in plasma and urine in the presence of
low plasma Met concentrations.
Approximately 90% of reported patients with the cblC
defect present with the severe, infantile, early-onset form
of the disease [3,4]. Characteristic clinical manifestations
of the infantile onset cblC defect are feeding difficulties
and failure to thrive, developmental delay, microcephaly,
seizures and muscular hypotonia, decreased visual acuity
due to pigmentary retinopathy and nystagmus. The true
incidence of the late-onset cblC defect is probably higher
than presently reported since in many cases the diagnosis
may be missed.
The early-onset form of the cblC defect is associated
with the frameshift mutation c.271dupA in Europeans,
with the c.331C > T nonsense mutation in the French-
Canadian, Acadian and Cajun populations, and with the
c.609G >A nonsense mutation in the Han Chinese popu-
lation. The c.394C > T nonsense mutation is encountered
most frequently in late-onset patients from Portugal, Italy,
Arabian and Asian countries, while the c.482G >A mis-
sense mutation has been reported in single patients from
Europe [5,6] and China [7]. There is evidence that the
c.394C > T mutation might result in a truncated protein
with residual function thus explaining its association with
late rather than early onset disease. MMACHC mRNA
expression studies showed that cell lines harbouring the
c.394C > T mutation had significantly higher levels of
transcript compared to cells carrying mutations associated
with early-onset disease [6]. In patients who are com-
pound heterozygous for e.g. a missense mutation and
c.271dupA, the phenotype seems to be predominantly
determined by the “milder” mutation [5].
In two large series of cblC patients reported in the litera-
ture, 26% [3] and 11.4% [4] of the patients – the great
majority with disease onset in the first year of life - died. In
survivors, neurological and eye disease progressed despite
treatment [4]. Even in infants diagnosed by newborn
screening and treated early in life, neurological and eye dis-
ease progresses and long-term neurocognitive outcome is
significantly impaired [8]. In the above cited series, onset
was classified as late in six out of 60 patients [3], with first
symptoms between age four and fourteen and in ten out
of 88 patients [4] with onset between > twelve months and
13.5 years respectively. Other late-onset cases have been
presented as case reports or small series. Clinical manifes-
tations in late-onset patients are significantly different
from the early-onset form and very heterogeneous [4] and
thus late-onset disease may be underdiagnosed.
The aims of this report are to i) systematically review pub-
lished data on the clinical spectrum of the late-onset cblC
defect; ii) evaluate treatment approaches, biochemical and
clinical response and general outcome; iii) illustrate the types
of clinical presentation; iv) discuss ways to diagnosis and
highlight clinical signs which should prompt the consider-
ation of inborn errors of metabolism (IEM) beyond infancy.
Methods
The Pubmed and the Cochrane databases were searched
using the terms “cobalamin; cblC; MMACHC, combined
methylmalonic aciduria homocystinuria, MMA, homocyst-
eine”. The terms were combined with “adult onset, late on-
set, review, case, case series”. In addition, references listed
in the papers retrieved by this method were screened. All
cases with onset of the disease >12 months were included
[4]. Data on clinical symptoms and biochemical and genetic
data were pooled for analysis whenever the description of
the cases allowed.
Written informed consent was obtained from all three
patients for publication of their case reports.
Results
Twenty-five reports on cases and case series were
selected as relevant to the topic and containing details
on clinical signs and symptoms in late-onset cblC cases.
Data on all parameters of interest where not consistently
given in the reports and are thus reported for varying
numbers of cases according to availability of data.
The reports covered 58 cases, 30 females and 22 males
[no information on gender available for six patients].
Three clinically asymptomatic individuals but with the
typical biochemical profile of the disease were reported
[9-11]. One clinically asymptomatic female had been
identified by investigations following the observation of
low free carnitine in her child’s newborn screening [11].
One female and one male asymptomatic patient respect-
ively were diagnosed by family screening after diagnostic
workup in their symptomatic siblings [9,10].
The male (n = 21) to female (n = 28) distribution in 49
symptomatic patients was uneven (ratio 0.75).
Table 1 summarizes the information on gender, age and
clinical signs at presentation, treatment and outcome in
the published cases (not including the three new cases
presented in this report). Descriptions of clinical signs and
symptoms were extracted from reports on 55 symptomatic
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Table 1 Age at first symptoms, clinical presentation, treatment and outcome in 58 late-onset cblC cases
No. Reference Age at onset Sex Clinical presentation Treatment Outcome
Years OH-Cbl Betaine Folate Carnitine Met
1 [12] 1.25 F PAH x Complete recovery
2 [13] 1.5 M PAH, HUS Untreated Deceased without diagnosis
3 [7] 1.5 F No information available No information available No information available
4 [7] 1.5 F No information available No information available No information available
5 [7] 2 M Lethargy, convulsions, hypotonia No information available No information available
6 [7] 2 M No information available No information available No information available
7 [10] 2,5 M Asymptomatic Untreated No information available
8 [13] 2,5 M PAH, HUS x Deceased
9 [14] 3 M PAH, HUS Untreated Deceased without diagnosis
10 [13] 3 M PAH, HUS Untreated Deceased without diagnosis
11 [7] 3.5 M Cognitive decline, lethargy, convulsions No information available No information available
12 [13] 4 F PAH, HUS x Progressive PAH
13 [15] 4 F HUS x x x Complete recovery
14 [16] 4 F Cognitive decline, neuropathy, ataxia x x x Improvement, mild cognitive
impairment, neurological sequelae
15 [17] 6 F HUS x x x Chronic renal failure
16 [18] 7 F Neuropathy, myelopathy, cognitive impairment, epilepsy x x Cognition improved, seizures
resolved, neurological sequelae
17 [17] 8 F HUS x x x Renal parameters improved
18 [19] 10 F Acute cognitive decline, anorexia, catatonia, psychosis,
seizures. Brain volume loss, thinned corpus callosum
x x Seizures and psychiatric
symptoms improved
19 [20] 11 F Cognitive decline, behavioral changes, ataxia, myoclonic jerks x x x x Complete recovery
20 [15] 11 M HUS, hypertensive encephalopathy, coma, convulsions x x x Complete recovery
(but antihypertensive drugs necessary)
21 [9] 12 F Ataxia, neuropathy, myelopathy, mild neuropsychiatric symptoms. x Improved; neurological sequelae
22 [21] 13 F Cognitive decline, ataxia/dysarthria, EEG abnormal x Cognition improved,
neurological sequelae
23 [13] 14 F PAH, HUS x “Stable” disease
24 [19] 14 F Cognitive decline, depression, ataxia, seizures,
neuropathy/myelopathy
x x x Improved; neurological sequelae
25 [10] 14 M Acute psychosis, mental retardation Untreated No information available
26 [22] 16 F Thromboembolism, neuropathy, myelopathy, psychiatric symptoms x x x x Disease progression
27 [23] 16 M Atypical glomerulopathy x x x Coma, deceased
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Table 1 Age at first symptoms, clinical presentation, treatment and outcome in 58 late-onset cblC cases (Continued)
28 [24] 18 F Glomerulonephritis; psychiatric symptoms, cognitive impairment,
recurrent thromboses, pulmonary embolism, seizures, neuropathy,
myelopathy, cortical atrophy, leukoencephalopathy,
corpus callosum agenesis
x x x Deceased after initial improvement
29 [25] 20 M HUS, renal failure, malignant hypertension x x x Improved, renal function stable
30 [26] 20 M Neuropathy, myelopathy, progressive encephalopathy, confusion,
deep venous thrombosis, progressive respiratory failure
x x Improved, neurological sequelae
31 [18] 22 F Triggered by pregnancy/caesarian section: Sluggish
response, neuropathy
x x Complete recovery
32 [27] 23 M Cognitive impairment, ataxia, neuropathy,
spinal cord myelin lesions
x x x x Improved, neurological sequelae
33 [22] 24 F Myelopathy x x x x Moderate myelopathy
34 [9] 29 F Asymptomatic Untreated Asymptomatic
35 [11] 29 F Asymptomatic x Biochemical response
36 [28] 32 F Progressive neuropathy, myelopathy, optic disk
pallor, leukopenia
Untreated Deceased without diagnosis
37 [24] 33 F Glomerulonephritis, recurrent deep venous thrombosis. x x x No more thromboses
38 [29] 36 F Neuropathy, psychiatric symptoms x x x Mental status improved,
neurological sequelae
39 [30] 38 M Hypertension, seizures, progressive confusion,
progressive periventricular white matter lesions
x x x Complete recovery
40 [18] 40 M Cognitive decline, hallucinations, neuropathy,
myelopathy, brain atrophy.
x x Complete recovery
41 [24] 41 M Depression, neuropathy, myelopathy, periventricular
leucoencephalopathy, abnormal signal in spinal
cord myelin
x x x Overall improvement. Spinal
cord myelin lesion disappeared
42 [28] 44 F Cognitive decline, optic disk pallor, venous thrombosis,
pulmonary embolism
Untreated Deceased without diagnosis
43-48 [3] 4-14 n.a. No individual information reported No information available N = 5 “very positive”; n = 1
“moderately impaired”
49-58 [4] 1-13.5 5 M No individual information reported No information available Overall reduction of symptoms
5 F
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patients [Figure 1]. Overall, cognitive decline/impairment
was the most frequent symptom, followed by neurological
symptoms such as affections of the spinal cord myelin,
ataxia and seizures. Haemolytic uraemic syndrome (HUS)
and pulmonary arterial hypertension (PAH) were often as-
sociated. Macrocytosis or macrocytic anaemia were present
in less than 20% of cases. Glomerulopathies as well as
thromboembolic events were rarely observed.
Information on age at disease onset was available for 39
symptomatic patients (mean 15 years; median 12 years,
range 1.3-44 years) [Figure 2]. The frequency of symptoms
differs markedly over the lifespan. Age specific patterns of
the disease are depicted in Figure 3. HUS (median age at
onset 6; mean 7.8, range 1.25-20 yrs) and PAH (median
age at onset 3; mean 4, range 1.25-14 yrs) were the most
frequent symptoms in very young children. In older
children/adolescents psychiatric symptoms (median age at
onset 14; mean 21.6, range 10-42 yrs), ataxia/dysarthria
(median age at onset 16; mean 20.8, range 4-44 yrs) and
cognitive decline (median age at onset 17; mean 19, range
4-34 yrs) were most frequent; while in adults, in addition
to cognitive decline and ataxia/dysarthria, thrombo-
embolic events (median age at onset 29; mean 28.5, range
16-44 yrs), neuropathy/myelopathy (median age at onset
23; mean 27.3, range 12-44 yrs) and non-HUS renal
disease (glomerulopathies) (median age at onset 39; mean
34.4, range 16-42 yrs) were dominant features.
Outcome of the disease ranged from death in eight
patients (in five of them, the diagnosis could only be
established post mortally) to complete recovery in seven
treated patients. In the reviewed sample, neurological and
cognitive improvement occurred in eleven patients; renal
functions stabilized in two patients. Clinical symptoms
were considered to generally respond to treatment in the
cohorts reported by Fischer et al. [4] and Rosenblatt et al.
[3] [Table 1].
Magnetic resonance imaging (MRI) findings were
reported in more detail for seventeen patients. Normal
brain imaging was present in two symptomatic patients.
Brain volume loss was observed in eight patients. Brain
white matter lesions were present in seven patients and
periventricular (nearly) confluent white matter hyperin-
tensities in T2 images seemed a distinct pattern. Spinal
cord myelin pathology was reported in four cases, labelled
as spinal infarct in one and described as high intensity
signals in T2-weighted images in three patients.
Time between first symptoms and diagnosis was men-
tioned in the reports on eighteen cases and ranged from
three months to more than 20 years (data not shown).
At diagnosis, mean tHcy was 138 μmol/L (n = 31; range
28–309 μmol/L; reference range 5–15) and decreased in all
patients under treatment to a mean of 35 μmol/L (n = 15;
range 8–169 μmol/L). Mean Met was initially low with
11.5 μmol/L (n = 17; range 4–34 μmol/L; reference range
20–45) and increased to 33 μmol/L (n = 11; range 12.7-
62 μmol/L). Mean MMA in urine at disease onset was
1950 μmol/mmol creatinine (n = 13; range 118–5558 μmol/
mmol creatinine; reference range < 10) and decreased to
98 μmol/mmol creatinine during follow-up (n = 7; range
5.8-250 μmol/mmol creatinine).
Information on genotype was available for 42 individ-
uals, including the three new cases presented in this paper.
The c.271dupA (21%), c.394C > T (21%) and c.609G >A
(11%) were the most frequent mutated alleles in this co-
hort of late-onset patients. Homozygosity for the c.394C >
T mutation –a genotype which has been described before
to be associated with the late-onset cblC defect [5]- was
present in seven individuals and thus constituted the most
frequent genotype in this population. Homozygosity for
the c.271dupA mutation, which is associated with the
early-onset cblC defect, was present only in a single
late-onset patient [Table 2].
%
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Figure 1 Frequency of clinical signs and symptoms in 55 patients with the late-onset cblC defect.
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Illustrative unreported cases
Case 1: Psychiatric symptoms in adolescence and HUS
in adulthood
A 23-year-old Portuguese male from a non-consanguineous
family came to medical attention at the age of 23 years.
History revealed that the patient’s sister had died at age
18 months from an unknown condition. The patient had
had trouble at school due to attention deficits and aggres-
sive behavior and left school at age fourteen. A depressive
episode and excessive drug consumption occurred at age
twenty. At age twenty-two, he was admitted to a psychi-
atric ward due to “strange” behavior, anxiety and signs of a
depersonalization disorder.
On admission, the patient reported one-month history
of progressive asthenia and shortness of breath when
walking, upper abdominal pain, reduced appetite and
unintended weight loss of 14 kg within two months. Ar-
terial hypertension (blood pressure 200/110 mmHg) was
present and ophthalmoscopy showed a grade III retinop-
athy with hemorrhages compatible with chronic hyper-
tension. The patient had no impairment of visual acuity
or nystagmus at any time.
Laboratory data on admission revealed macrocytic
anemia (haemoglobin 73 g/L, mean corpuscular volume
99.5 fl), high level of reticulocytes (50.4%o, reference
range 5–15), abundant fragmentocytes, and low level of
platelets (88’000/mm3). Urea (21.7 mmol/L, reference
range 2.8-7.1), and creatinine (523 μmol/L, reference
range 62–106), were significantly elevated and protein
(56 g/L reference range 61–79), was low in the presence
Figure 2 Age at disease onset (cumulative) in 39 patients with the late-onset cblC defect.
Figure 3 Number of patients and age at onset for main clinical symptoms in 39 patients with the late-onset cblC defect. * Each column
represents one patient.
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of proteinuria and haemoglobinuria. Renal and urinary
tract ultrasound was unremarkable. Echocardiography
showed marked concentric left ventricular hypertrophy
with a moderately dilated left atrium. A total tHcy value
of >250 μmol/L (reference range 5–15) was apparently
unnoticed.
Under the diagnosis of malignant hypertension with
secondary renal failure and/or HUS, antihypertensive
therapy was initiated. Twenty-four hours after admis-
sion, the electrocardiogram showed inverted T waves in
the presence of increased troponin levels and the patient
was transferred to the intensive care unit. Blood pressure
was difficult to stabilize even with consecutive and com-
bined used of six antihypertensive drugs. At this time,
the patient had two grand mal seizures.
End-stage renal failure developed within 15 days and
renal replacement therapy was started. After six weeks
in hospital, the patient was discharged with the diagnosis
of malignant hypertension with secondary microangiop-
athy, renal failure, retinopathy and cardiomyopathy.
Fifteen months later, while clinically stable on renal
replacement therapy, tHcy was measured as part of rou-
tine follow-up and the concentration was again highly
elevated with 353 μmol/L. Met (16 μmol/L) was low and
MMA was not assessed. The cblC defect was proven
in cultured fibroblasts by Met and serine formation,
[57Co]-Cobalamin uptake and coenzyme synthesis,
and propionate incorporation [31]. Molecular genetic
analysis revealed homozygosity for a c.565C >A (p.R189S)
missense mutation in exon 4. This mutation had previously
Table 2 Genotypes of 42 patients with the late onset cblC defect
Allele 1 Allele 2 N Reference
Nucleotide change Amino acid change Exon Nucleotide change Amino acid change Exon
c.271dupA p.Arg91Lysfs*14 2 c.271dupA p.Arg91Lysfs*14 2 1 [4]
c.271dupA p.Arg91Lysfs*14 2 c.276G > T p.Glu92Asp 2 2 [13]
c.271dupA p.Arg91Lysfs*14 2 c.82-9_12delTTTC r.spl? Intron 1 1 [4]
c.271dupA p.Arg91Lysfs*14 2 c.347 T > C p.Leu116Pro 3 3 [4,22]
c.271dupA p.Arg91Lysfs*14 2 c.365A > G p.His122Arg 3 1 [24]
c.271dupA p.Arg91Lysfs*14 2 c.389A > G p.Tyr130Cys 3 1 [25]
c.271dupA p.Arg91Lysfs*14 2 c.394C > T p.Arg132* 3 1 [4]
c.271dupA p.Arg91Lysfs*14 2 c.440G > C p.Gly147Ala 4 2 [28]
c.271dupA p.Arg91Lysfs*14 2 c.482G > A p.Arg161Gln 4 2 [26,29]
c.271dupA p.Arg91Lysfs*14 2 c.565C > A p.Arg189Ser 4 1 [24]
c.271dupA/c.565C > A p.Arg91Lysfs*14/ 2 c.565C > A p.Arg189Ser 4 1 [4]
c.276G > A p.Glu926Glu [p.(=)] 2 c.442_444delinsA p.Val148Metfs*33 4 1 [13]
c.276G > A p.Glu926Glu [p.(=)] 2 c.14_24del11 p.Val5Glufs*25 1 1 [13]
c.276G > T p.Glu92Asp 2 c.276G > T p.Glu92Asp 2 1# -
c.276G > T p.Glu92Asp 2 c.442_444delinsA p.Val148Metfs*33 4 1 [14]
c.347 T > C p.Leu116Pro 3 c.347 T > C p.Leu116Pro 3 1#
c.365A > G p.His122Arg 3 c.457C > T p.Arg153* 4 1 [24]
c.392_394del p.Gln131del 3 c.392_394del p.Gln131del 3 1 [27]
c.394C > T p.Arg132* 3 c.394C > T p.Arg132* 3 7 [4,16,19]
c.394C > T p.Arg132* 3 c.468_469delCT p.Trp157Valfs*24 4 1 [4]
c.464G > A p.Gly155Glu 4 c.464G > A p.Gly155Glu 4 1 [13]
c.482G > A p.Arg161Gln 4 c.82-1G > A r.spl? Intron 1 1# -
c.482G > A p.Arg161Gln 4 c.609G > A p.Trp203* 4 2 [18]
c.484G > T p.Gly162Trp 4 c.484G > T p.Gly162Trp 4 1 [12]
c.609G > A p.Trp203* 4 c.609G > A p.Trp203* 4 2 [7]
c.609G > A p.Trp203* 4 c.394C > T p.Arg132* 3 1 [7]
c.609G > A p.Trp203* 4 c.658_660delAAG p.Lys220del 4 1 [7]
c.609G > A p.Trp203* 4 c.1A > G p.Met1? 1 1 [18]
c.1A > G p.Met1? 1 n.d. 1 [7]
#new reported cases; n.d. = not detected.
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been described in compound heterozygosity in two
Spanish late-onset patients [32], one late onset patient of
unspecified origin [1] and two Portuguese early-onset
patients [33].
Initially, tHcy levels around 37–66 μmol/L were
achieved with daily IV OH-Cbl injections and oral beta-
ine (16 g/d), carnitine (1 g/d) and folate (5 mg/d). Over
the next five years, median tHcy level was 70 μmol/L
(range24 to 149 μmol/L), median blood MMA was
18 μmol/L (ref <0.28) and median Met was 28 μmol/L
under sometimes less than optimal compliance. In the
meantime, the patient underwent renal transplantation
and during the following five years, renal function was
stable. Cardiac morphology normalized but antihyper-
tensive treatment with a combination of three drugs
remained required. Interestingly, psychosocial adapta-
tion and functioning improved markedly. The patient
became able to sustain a lasting relationship and family
life, to keep social contacts and to pursue a successful
professional career.
Case 2: Neuropathy, subacute and combined degeneration
of the spinal cord, cognitive impairment, depression and
thromboembolism
A previously healthy, twenty-six year old Austrian male
presented with the clinical symptoms of a symmetric
sensorimotor neuropathy. Family history was uneventful
and without evidence for consanguinity. The condition
was progressive and the diagnosis of an immune-mediated
neuropathy was established and immunosuppressive treat-
ment initiated. Nevertheless, the condition worsened and
a myelopathy on basis of vitamin B12 deficiency was
suspected, especially when the patient developed subacute
thoracal myelopathy with hypoaesthesia, disturbance of
position sense, pathological reflex pattern and sudden gait
difficulties at the age of 30 years. The MRI scan of the
myelon supported this idea but due to repeatedly normal
vitamin B12 serum levels, the hypothesis was no longer
pursued. At this time, the patient additionally complained
about an unintended weight loss of 8 kg due to loss of
appetite; impaired short-term memory, concentration
problems and confusion. In parallel, the patient developed
deep vein thrombosis, promoted by reduced physical ac-
tivity following an ankle joint injury. Further investigations
revealed peripheral pulmonary embolism, attributed to a
heterozygous mutation in the prothrombin gene. Several
months later due to progressive neurological and psychi-
atric symptoms, the patient was transferred for a second
opinion to a tertiary center. Besides the sensory ataxic gait
disorder due to neuropathy and myelopathy, the patient
presented with depression and cognitive impairment in-
cluding slow mentation, memory impairment, attention
deficits, and executive impairment. Metabolic investiga-
tions considerably increased tHcy (228–264 μmol/L) low
Met (7.7 μmol/L) and highly elevated urinary MMA
excretion in qualitative analysis in the presence of normal
vitamin B12 and holotranscobolamin levels. The cblC
defect was proven by enzymatic and complementation
studies in cultured fibroblasts as described [31]. Molecular
genetic analysis of the MMACHC gene revealed a splice
site mutation in intron 1 (c.82-1G >A) and a missense
mutation in exon 4 (c.482G > A).
Treatment with OH-Cbl 3×2 mg/week IM, betaine
2×6 g PO/day, Folic acid 1×5 mg PO/day was initiated
and resulted in resolved cognitive and psychiatric symp-
toms and improved myelopathy. Biochemical response
was marked; tHcy values and MMA excretion immedi-
ately decreased while Met remained rather low. There-
fore, OH-Cbl treatment was adapted to 3×5 mg IM/ week
and methionine 2×125 mg/d was supplemented. Following
this scheme, the patient widely recovered but residues of
myelopathy remained. His main complaints are impair-
ment of sensory function and hypoaesthesia in the gluteal
region and predominantly the lower legs while motor
functions recovered almost fully. Evoked potentials show a
significant improvement but no resolution of the axonal
damage. No thrombosis occurred during four years of
follow-up; renal, liver and cardiac function as well as visual
acuity and ophthalmoscopy findings were normal. THcy
concentrations remain stable between 50 and 60 μmol/L,
Met in the upper normal range between 40 and 50 μmol/L
and MMA excretion has decreased to 65 mmol/mol
creatinine (reference range <10).
Case 3 Apathy, reversible white matter abnormalities,
paresis and respiratory insufficiency
A 34-year-old woman of Moroccan descent was admitted
to the neurology department for evaluation of increasing
apathy, confusion and tetraparesis. Family history was
unremarkable and the patient did not smoke, drink
alcohol, or use illicit drugs.
Weakness and an unsteady, staggering gait together
with loss of tendon reflexes of the lower extremities had
occurred two years earlier, at that time identified as sen-
sorimotor demyelinating polyneuropathy. Cerebrospinal
fluid (CSF) analysis was normal and serologic testing for
antiganglioside antibodies was negative. Treated with
intravenous immune globulin the patient made a re-
markable recovery. In the recovery phase, an anxiety dis-
order was diagnosed. However, over the next 12 months,
the classification of her psychiatric illness was revised
several times and various combinations of psychiatric
medications were prescribed.
Approximately four weeks before admission, during a
stay in Morocco, the patient discontinued her psychiatric
medications and was acutely hospitalized due to symp-
toms consistent with neuroleptic malignant syndrome. In
the following, after her return from Morocco her family
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noticed increasing lethargy and weakness, resulting in
inability for self-care and communication.
Based on neurophysiological testing acute axonal poly-
neuropathy was diagnosed. In addition, MRI of the brain
with administration of gadolinium revealed large areas
of signal abnormality without enhancement predomin-
antly involving the white matter of both hemispheres,
and extending to the midbrain structures. CSF analysis
yielded minimal increase of lactate, normal cell counts,
protein and glucose. Extensive testing for autoimmune
diseases as well as infectious and malignancy-associated
aetiologies, ophthalmological investigation and analysis of
exposure to heavy metals or organic chemicals revealed
normal results. An intermittent episode of abdominal pain
prompted suspicion of porphyria and indeed, urine and
blood tests revealed mild elevation of porphobilinogen
and delta-aminolevulinic acid. A treatment course with
hemearginate was instituted presumptively until genetic
testing for porphyria proved negative.
Despite symptomatic treatment, the patient’s condi-
tion progressively declined over the next four weeks
resulting in respiratory failure requiring intubation and
mechanical ventilation. Further, bilateral deep venous
thrombosis occurred despite consistent administration
of prophylactic subcutaneous low-molecular-weight
heparin.
The patient was transferred to the neurocritical care
unit for further evaluation. Repeat MRI of the neuroaxis
showed progression of the signal abnormalities with
additional involvement of the spinal cord. A systematic
review of previous investigations and clinical presenta-
tion prompted metabolic workup which revealed ele-
vated plasma tHcy (53.3 μmol/L), low Met (9.6 μmol/L)
and MMA-uria (1168 mmol/mol creatinine) in the
presence of normal serum vitamin B12 levels. The cblC
defect was proven by enzymatic and complementation
studies in cultured fibroblasts and MMACHC mutation
analysis identified a homozygous mutation (c.347 T > C)
which has previously been reported [4,22]. Treatment
with intravenous injections of OH-cobalamin (1000 μg)
was started, daily for two weeks, then three times a
week for the next four weeks, followed by weekly sup-
plementation. After four weeks of treatment, brain and
spine MRI showed marked reduction of the white mat-
ter abnormalities and tHcy, Met and MMA concentra-
tions had returned to normal. The patient improved
steadily and could be weaned off the ventilator. After
weaning off centrally acting medications the patient
was able to follow commands, and within two months,
she was able to walk with assistance. However, persist-
ent neuropsychological deficits including confusion
and amnesia required aftercare in a residential-care
facility following six month of intensive neurological
rehabilitation.
Discussion
This report summarizes the clinical spectrum of the late-
onset cblC defect and adds three new cases. The review of
thirty-nine reported cases with disease onset >12 months
identifies age-associated patterns and reveals that late-
onset cblC disease cannot be considered a homogeneous
clinical entity.
A distinct group of young children present with a
rather uniform disease with HUS and PAH. The course
in these children has mostly been rapidly progressive
and outcome was deleterious in four out of six children.
HUS was the most frequent symptom in children under
six years.
From school age and through adolescence the pattern of
the disease changes and becomes dominated by psychi-
atric symptoms, cognitive decline and ataxia with HUS,
neuropathy/myelopathy, macrocephaly and seizures. In
adults, thrombosis, neuropathy, myelopathy and dementia
are the most prominent features accompanied by glom-
erular pathologies other than HUS and psychiatric
symptoms. Macrocytosis or macrocytic anaemia are not
consistently reported. At all ages, the disorder may
present with acute or insidious onset, and show sudden
deterioration as well as long stable phases.
The pathophysiologic mechanisms behind this severe
multisystemic disease have not completely been eluci-
dated at present. However it has been shown that de-
myelination in the cblC defect (and most probable also
in acquired vitamin B12 deficiency) seems associated
with low levels of S-adenosylmethionine resulting from
the impaired remethylation of Hcy to Met [34]. Met de-
ficiency may also be involved in the impairment of cog-
nitive development by hampering methyl group transfers
essential for the synthesis of creatine [35], regulation of
gene expression, nucleotide metabolism and many other
metabolic pathways [36]. Acute encephalopathic features
and long-term neurotoxicity have also been attributed to
high MMA levels in the brain especially since the hy-
pothesis of extensively high concentrations of dicarbox-
ylic acids in the brain due to a “trapping” mechanism
has been developed [37]. MMA is also known to be in-
volved in chronic renal failure [38] by altering and impair-
ing mitochondrial energy metabolism [36]. Vascular disease
and thrombosis have initially been attributed to isolated ele-
vation of tHcy concentrations. However, with the observa-
tion of HUS as specific clinical pattern of the cblC
defect -which has not been observed in classical homocys-
tinuria, a disease causing high levels of tHcy and Met- it
has been suggested that the specific involvement of small
vessels causing HUS may result from combined high tHcy
and low Met concentrations [36]. It is also of note that the
characteristic eye disease frequently encountered in the
early-onset cblC defect with retinopathy and loss of visual
acuity differs significantly from the eye involvement in
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classical homocystinuria and may therefore not be
explained by isolated high tHcy concentrations.
Due to the wide age distribution at disease onset (1.3-
44 years; mean: 15; median 12 years) and the variable
clinical phenotypes paediatricians, as well as adult physi-
cians (e.g. neurologists, nephrologists, psychiatrists, im-
munologists, haematologists and haemostaseologists)
are involved in the clinical and diagnostic workup of
late-onset cblC patients. Like in other rare IEM, time
between onset of disease and diagnosis in most cases is
extremely long and a subgroup of reported patients even
died without diagnosis [13,20]. Since paediatricians have
historically covered the field of IEM, adult physicians
sometimes are not too familiar with IEM. However, the
late-onset cblC defect presents with many of the clas-
sical “textbook pictures” for IEM such as unclear alter-
ations of consciousness and general status, unexplained
progressive or intermittent neurological disease, unex-
plained thromboembolism, weight loss and loss of appe-
tite, or a systemic disease involving more than one organ
system. Additionally, history often reveals siblings or other
family members having suffered or even died from a simi-
lar or “unknown” systemic disease, pointing towards the
genetic origin of the disease. Reduction of the diagnostic
delay by raising awareness for IEM and lowering the
threshold for metabolic investigations would be of signifi-
cant benefit for the patients, because in contrast to the
majority of early-onset cblC patients, most late-onset pa-
tients respond to treatment with significant improvement
not only of biochemical parameters but also of clinical
manifestations. Earlier initiation of treatment could poten-
tially ameliorate the frequently reported neurological se-
quelae. Therefore, the establishment of adult metabolic
clinics and/or close cooperation of metabolic specialists
with general paediatricians and adult physicians are a
medical need.
In a large series of 88 patients with the cblC defect
(including 10 late-onset patients), a male to female ratio
of 1.93 was observed. Since the late-onset group in this
series encompassed five females and five males, the un-
even distribution is determined by the early-onset subgroup
[4]. In the reports summarized here, the male to female ra-
tio of 0.7 indicates that in contrast to the early-onset form,
the late-onset form of the cblC defect is more frequently
reported in females. However, both the series reported by
Fischer et al. and the present sample carry high risk of
selection and reporting/publication bias. Therefore the ob-
served gender differences need to be confirmed by samples
generated e.g. from the recently installed European network
and registry for homocystinurias and methylation defects
(https://www.ehod-registry.org/). Furthermore, there is no
evidence that females in general might have a milder dis-
ease course. Reports on two pairs of brothers [10,28] and
one pair of sisters [20] clearly demonstrate a significant
variation of clinical symptoms between siblings. Further-
more Boxer et al. report the case of a 42 year-old male with
late-onset cognitive impairment and his sister who had died
from severe, early-onset, progressive neurological disease at
age seventeen [30].
The three new exemplary cases illustrate the spectrum
of late-onset cblC disease in the adolescent/adult; under-
line the long delay from first symptoms to diagnosis,
and demonstrate both the impressive response to treat-
ment and the sequelae associated with delayed diagnosis
in this disorder. This observation suggests that diagnosis
by NBS and initiation of early treatment might result in
complete prevention of disease symptoms. However,
since experience with NBS for cblC [8] is very limited,
this question requires future research efforts.
Acute and chronic psychiatric symptoms either iso-
lated or accompanied by involvement of other organs or
on basis of impaired neurodevelopment have been de-
scribed in a large number of IEM in adolescents and
adults [39]. Since awareness for rare IEM presenting be-
yond infancy is still limited also in psychiatric special-
ists, many patients remain undiagnosed and without
specific treatment for years. Generally, indicators for
metabolic workup in patients with psychiatric symptoms
are fluctuation of symptoms and especially aggravation
of disease during catabolism, association with systemic
and/or neurological disease and abnormalities (e.g. white
matter alterations) revealed by imaging studies of the
central nervous system [22,39].
In patients with predominantly neurological manifesta-
tions such as myelopathy and neuropathy, clinicians
often feel reminded of diseases associated with e.g. ali-
mentary vitamin B12 deficiency, especially when macro-
cytosis or macrocytic anaemia accompany neurological
disease. Nevertheless, as soon as normal cobalamin con-
centrations in blood are measured, the hypothesis is
often dismissed. To avoid this pitfall, the measurement
of MMA in urine or in case of impaired renal function
also in plasma, completed by measurement of tHcy in
blood must be highlighted as the most precise method
to detect any functionally relevant “vitamin B12- associ-
ated problem” [40,41].
For several years, extensive tHcy measurement had
been recommended on basis of an assumed association
of mildly elevated tHcy concentrations with major com-
mon diseases such as cardiovascular disease, dementia,
thrombosis and stroke. Recently, tHcy assessment has
been disregarded in many settings due to the failure of
large epidemiological studies to prove these associations
for the general population [42-44]. Consecutively, even in
young, otherwise healthy adults with thrombosis, or in
early onset dementia, it might well be that tHcy is not
assessed. It must be kept in mind that this approach will
lead to a significant number of patients, encompassing not
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only cblC patients but also individuals with other IEM
causing hyperhomocysteinemia (e.g. classical homocysti-
nuria) being missed. One positive exception in this regard
is the recent guideline for the workup in patients with
atypical HUS, which addresses intracellular disorders of
cobalamin metabolism as a differential diagnosis [45].
Conclusion
The late-onset cblC defect with disease onset beyond the
typical infantile presentation and IEM in general are a
neglected field of clinical perception and medical workup.
Raising awareness for this group of disorders has the
potential to improve patients’ outcome and perspective by
timely initiation of targeted treatment.
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